Lynx Investment Advisory’s AbbVie ABBV Stock Holding History

Lynx Investment Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$739K	Buy	2,938 +1,062	+57%	+$228K	0.24%	104
2026 Q1	$408K	Sell	1,876 -132	-7%	-$29.3K	0.2%	114
2025 Q4	$459K	Buy	2,008 +8	+0.4%	+$1.82K	0.25%	91
2025 Q3	$463K	Buy	2,000 +7	+0.4%	+$1.43K	0.28%	82
2025 Q2	$370K	Buy	1,993 +23	+1%	+$4.28K	0.24%	92
2025 Q1	$413K	Buy	1,970 +11	+0.6%	+$2.14K	0.28%	80
2024 Q4	$348K	Buy	1,959 +248	+14%	+$45.6K	0.24%	95
2024 Q3	$338K	Buy	1,711 +101	+6%	+$18.9K	0.24%	91
2024 Q2	$276K	Buy	+1,610	New	+$267K	0.2%	105

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

KeyBank National Association Cleveland, Ohio $30.4B AUM 27.51% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

Lynx Investment Advisory's ABBV Position: Q2 2026 in Review

Lynx Investment Advisory increased its AbbVie (ABBV) stake by 57% in Q2 2026, buying an estimated $228K and bringing the position to 2,938 shares worth $739K. The position accounts for 0.24% of the portfolio, ranked #104.

Lynx Investment Advisory first reported a position in ABBV in Q2 2024 and has held it in 9 quarters since. 1,680 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Lynx Investment Advisory held 2,938 shares of AbbVie worth $739K as of Q2 2026.
Lynx Investment Advisory bought 1,062 AbbVie shares in Q2 2026, an estimated $228K.
AbbVie made up 0.24% of Lynx Investment Advisory's portfolio in Q2 2026, its #104 holding.
Lynx Investment Advisory first reported a position in AbbVie in Q2 2024 and has held it in 9 quarters since.
1,680 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lynx Investment Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.